News

New Cellular Atlas of Meningioma Reveals Immune Signatures Linked to Tumor Recurrence

Research Advances /

Researchershave created the most detailed map to date of meningioma, the most common brain tumor in adults. The study found that the tumor’s surrounding environment, particularly immune cells known as myeloid cells, plays a major role in determining how the cancer grows, returns, and responds to treatment. Using advanced technologies such as single-cell sequencing and […]

New Cellular Atlas of Meningioma Reveals Immune Signatures Linked to Tumor Recurrence Read More »

Teclistamab Plus Daratumumab Shows Strong Survival Benefit in Relapsed Multiple Myeloma (MajesTEC-3)

Treatment /

Teclistamab (Tecvayli) combined with daratumumab has emerged as a strong second-line treatment option for patients with relapsed or refractory multiple myeloma, especially for those who relapse after frontline quadruplet therapy and are not candidates for CAR T-cell therapy. In the phase 3 MajesTEC-3 trial involving 587 patients, the combination significantly outperformed standard therapy. Median progression-free

Teclistamab Plus Daratumumab Shows Strong Survival Benefit in Relapsed Multiple Myeloma (MajesTEC-3) Read More »

Trastuzumab Pamirtecan Shows Strong Activity in HER2-Positive Advanced Endometrial Cancer

Treatment /

Trastuzumab pamirtecan (T-Pam; BNT323/DB-1303), a HER2-targeting antibody-drug conjugate, showed promising results in patients with advanced or recurrent HER2-expressing endometrial cancer who had progressed after chemotherapy and immunotherapy. In a phase 2 study of 145 patients with a median follow-up of 13.2 months, the treatment achieved a median progression-free survival of 8.0 months and a median

Trastuzumab Pamirtecan Shows Strong Activity in HER2-Positive Advanced Endometrial Cancer Read More »

Bulumtatug Fuvedotin Shows Promising Activity in Advanced Cervical Cancer in Early Clinical Trials

Clinical Trails /

Bulumtatug fuvedotin (9MW2821), a Nectin-4–targeting antibody-drug conjugate, showed promising activity in patients with recurrent or metastatic cervical cancer who had progressed after platinum-based chemotherapy.. In a phase 1/2 study of 53 patients, 73.6% experienced tumor shrinkage. The confirmed overall response rate was 32.08%, including one complete response and 16 partial responses. Disease control was achieved

Bulumtatug Fuvedotin Shows Promising Activity in Advanced Cervical Cancer in Early Clinical Trials Read More »

Liquid Biopsy Biomarker Model Improves Survival Prediction in Recurrent Ovarian Cancer

Research Advances /

Researchers reported validation of a liquid biopsy-based model that predicts overall survival in recurrent ovarian cancer. The model uses a combination of blood protein markers and clinical factors to improve patient risk stratification and guide future research. The analysis was based on data from the phase 3 ANITA/ENGOT-OV41/GEICO 69-O trial, testing an 8-variable model in

Liquid Biopsy Biomarker Model Improves Survival Prediction in Recurrent Ovarian Cancer Read More »

Iza-Bren Improves Survival and May Set New Standard for Advanced Triple-Negative Breast Cancer

Treatment /

Results from the phase 3 PANKU-Breast02 trial showed that izalontamab brengitecan (iza-bren), a bispecific antibody-drug conjugate targeting EGFR and HER3, significantly improved outcomes in patients with previously treated advanced or metastatic triple-negative breast cancer (TNBC). Among 418 patients, iza-bren reduced the risk of disease progression or death by 71%, achieving a median progression-free survival of

Iza-Bren Improves Survival and May Set New Standard for Advanced Triple-Negative Breast Cancer Read More »

New CRC Subtype Could Broaden Immunotherapy Eligibility

Research Advances /

A new multi-omics study has identified three molecular subtypes of colorectal cancer (CRC), with one subtype, known as CS3, showing strong potential for predicting response to immunotherapy. Researchers analyzed genetic, epigenetic, and molecular data and found that CS3 tumors are highly mutated, genomically unstable, and rich in immune activity. Importantly, CS3 includes a subset of

New CRC Subtype Could Broaden Immunotherapy Eligibility Read More »

Nirogacestat Demonstrates Durable Benefits for Progressive Desmoid Tumors

Treatment /

An expert discussion highlighted how treatment of desmoid tumors has changed in recent years. Because many of these rare soft-tissue tumors can remain stable or even shrink on their own, doctors now often recommend active monitoring rather than immediate surgery, which has a high risk of recurrence. However, patients with growing or symptomatic tumors usually

Nirogacestat Demonstrates Durable Benefits for Progressive Desmoid Tumors Read More »

Zanubrutinib Outperforms Ibrutinib in Indirect Comparison for First-Line CLL Treatment

Treatment /

A new analysis suggests that zanubrutinib may provide better outcomes than ibrutinib as a first-line treatment for patients with chronic lymphocytic leukemia (CLL). Researchers compared data from two separate Phase 3 clinical trials and adjusted for differences in patient characteristics to create a balanced comparison. The results showed that patients treated with zanubrutinib had a

Zanubrutinib Outperforms Ibrutinib in Indirect Comparison for First-Line CLL Treatment Read More »

Pumitamig Plus Chemotherapy Shows Strong First-Line Activity in Advanced NSCLC

Treatment /

Results from the Phase 2 ROSETTA Lung-02 study p suggest that pumitamig, an experimental bispecific antibody targeting PD-L1 and VEGF-A, may be a promising first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) when combined with chemotherapy. Among 40 patients enrolled in the study, the treatment achieved a 100% confirmed disease control rate.

Pumitamig Plus Chemotherapy Shows Strong First-Line Activity in Advanced NSCLC Read More »